<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e56a32d1-031d-4453-b0c3-05f5a530e5d4"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <effectiveTime value="20110818"/>
   <setId root="f8035130-1a60-4ba3-a9be-b1a739c946db"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="786036330" root="1.3.6.1.4.1.519.1"/>
            <name>STAT RX USA LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="786036330" root="1.3.6.1.4.1.519.1"/>
                        <name>STAT RX USA LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="relabel"/>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="repack"/>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="632afb4e-6f6a-4205-b63a-cf10efb042f5"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL listing data elements section"/>
               <effectiveTime value="20110818"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="16590-434" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MELOXICAM<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>MELOXICAM</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="29300-124" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="7.5" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MELOXICAM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MELOXICAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="390RMW2PEQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K29/32</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-434-10" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-434-20" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="28" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-434-28" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-434-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="56" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-434-56" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-434-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="180" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-434-82" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-434-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20070307"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077927" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">U;L;7;5</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="16590-469" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MELOXICAM<suffix/>
                        </name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>MELOXICAM</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="29300-125" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="15" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MELOXICAM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="VG2QF83CGL" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MELOXICAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRISODIUM CITRATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="390RMW2PEQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K29/32</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-469-15" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="28" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-469-28" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-469-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="56" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-469-56" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-469-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1">
                                 <translation code="C48542" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              </numerator>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="16590-469-90" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20070307"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA077927" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">U;L;15</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="9a9eccc6-59ab-4e15-a8c9-e9604d56276a"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <text>
                  <linkHtml href=""/>WARNING: RISK OF CARDIOVASCULAR AND GASTROINTESTINAL EVENTS<linkHtml href=""/>
                  <linkHtml href=""/>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Cardiovascular Risk </content>
                  </paragraph>
                  <list listType="unordered" ID="i932e09fc-111b-4deb-8769-0b71a73ce8d4">
                     <item>
                        <content styleCode="bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause an 
increased risk of serious cardiovascular (CV) thrombotic events, myocardial 
infarction, and stroke, which can be fatal. This risk may increase with duration 
of use. Patients with cardiovascular disease or risk factors for cardiovascular 
disease may be at greater risk [see </content>
                        <content styleCode="italics">
                           <linkHtml href="#ID44">Warnings and Precautions (5.1)</linkHtml>]. </content>
                     </item>
                     <item>
                        <content styleCode="bold">Meloxicam tablets are contraindicated for the treatment of 
perioperative pain in the setting of coronary artery bypass graft (CABG) surgery 
[see </content>
                        <content styleCode="italics">
                           <linkHtml href="#ID39">Contraindications (4.2)</linkHtml> and 
<linkHtml href="#ID44">Warnings and Precautions (5.1)</linkHtml>]. </content>
                     </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Gastrointestinal Risk </content>
                  </paragraph>
                  <list listType="unordered" ID="ie8503b37-1738-4590-8303-25b0df6c2df9">
                     <item>
                        <content styleCode="bold">NSAIDs cause an increased risk of serious gastrointestinal 
(GI) adverse reactions including bleeding, ulceration, and perforation of the 
stomach or intestines, which can be fatal. These events can occur at any time 
during use and without warning symptoms. Elderly patients are at greater risk 
for serious gastrointestinal events [see </content>
                        <content styleCode="italics">
                           <linkHtml href="#ID46">Warnings and Precautions (5.2)</linkHtml>].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20110818"/>
            </section>
         </component>
         <component>
            <section>
               <id root="0d67d946-2088-46f3-8e21-82166d58d7cb"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1. INDICATIONS AND USAGE</title>
               <text>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>1.1 Osteoarthritis (OA)</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Meloxicam tablets are indicated for relief of the signs and 
symptoms of osteoarthritis [<content styleCode="italics">see <linkHtml href="#section-"> Clinical 
Studies (14.1)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>1.2 Rheumatoid Arthritis (RA)</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Meloxicam tablet are indicated for relief of the signs and 
symptoms of rheumatoid arthritis [<content styleCode="italics">see <linkHtml href="#section-"> Clinical Studies (14.1)</linkHtml>]. </content>
                  </paragraph>
               </text>
               <effectiveTime value="20110909"/>
            </section>
         </component>
         <component>
            <section>
               <id root="7410697a-68b6-4f32-9df7-da9ab605c04e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2. DOSAGE AND ADMINISTRATION</title>
               <text>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>2.1 General Instructions</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Carefully consider the potential benefits and risks of 
meloxicam tablets USP and other treatment options before deciding to use 
meloxicam tablets USP. Use the lowest effective dose for the shortest duration 
consistent with individual patient treatment goals [<content styleCode="italics">see <linkHtml href="#section-"> Warnings and Precautions (5.4)</linkHtml>]. </content>
                  </paragraph>
                  <paragraph>After observing the response to initial therapy with meloxicam tablets USP, 
adjust the dose to suit an individual patient's needs. </paragraph>
                  <paragraph>In adults, the maximum recommended daily oral dose of meloxicam tablets USP 
is 15 mg regardless of formulation. In patients with hemodialysis, a maximum 
daily dosage of 7.5 mg is recommended [<content styleCode="italics">see <linkHtml href="#section-"> Warnings and Precautions (5.6)</linkHtml>, <linkHtml href="#section-"> Use in 
Specific Populations (8.7)</linkHtml> and <linkHtml href="#section-"> Clinical Pharmacology 
(12.3)</linkHtml>]. </content>
                  </paragraph>
                  <paragraph>Meloxicam tablets USP may be taken without regard to timing of meals. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>2.2 Osteoarthritis</content>
                  <paragraph>
                     <linkHtml href="#section-"/>For the relief of the signs and symptoms of osteoarthritis 
the recommended starting and maintenance oral dose of meloxicam tablets USP is 
7.5 mg once daily. Some patients may receive additional benefit by increasing 
the dose to 15 mg once daily. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>2.3 Rheumatoid Arthritis</content>
                  <paragraph>
                     <linkHtml href="#section-"/>For the relief of the signs and symptoms of rheumatoid 
arthritis, the recommended starting and maintenance oral dose of meloxicam 
tablets USP is 7.5 mg once daily. Some patients may receive additional benefit 
by increasing the dose to 15 mg once daily.</paragraph>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="d046ef8b-2e21-48b2-825d-2fec3f051be5"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3. DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>
                     <linkHtml href=""/>Tablets: </paragraph>
                  <list listType="unordered" ID="iaf3af5fd-fb88-45c9-8275-0a628a9fd664">
                     <item>7.5 mg: Light yellow, round flat beveled edged tablet with UL debossed on 
one side and 7.5 debossed centrally on the other side. 
</item>
                     <item>15 mg: Light yellow, capsule shaped, biconvex, tablet with UL debossed on 
one side and 15 debossed centrally on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="cefbba31-b3eb-4ac1-8934-19e129bf1945"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4. CONTRAINDICATIONS</title>
               <text>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>4.1 Allergic Reactions</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Meloxicam tablets are contraindicated in patients with known 
hypersensitivity (e.g. anaphylactoid reactions and serious skin reactions) to 
meloxicam. </paragraph>
                  <paragraph>Meloxicam tablets should not be given to patients who have experienced 
asthma, urticaria, or allergic-type reactions after taking aspirin or other 
NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been 
reported in such patients <content styleCode="italics">[see <linkHtml href="#section-"> Warnings and 
Precautions (5.7</linkHtml>, <linkHtml href="#section-"> 5.13</linkHtml>)]. </content>
                  </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>4.2 Coronary Surgery</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Meloxicam tablets are contraindicated for the treatment of 
peri-operative pain in the setting of coronary artery bypass graft (CABG) 
surgery [<content styleCode="italics">see <linkHtml href="#section-"> Warnings and Precautions 
(5.1)</linkHtml>]. </content>
                  </paragraph>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="b840d80e-4550-4b9b-8945-573d0c1c6ce4"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5. WARNINGS AND PRECAUTIONS</title>
               <text>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.1 Cardiovascular Thrombotic Events</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Clinical trials of several COX-2 selective and nonselective 
NSAIDs of up to three yearsâ€™ duration have shown an increased risk of serious 
cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which 
can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a 
similar risk. Patients with known CV disease or risk factors for CV disease may 
be at greater risk. To minimize the potential risk for an adverse CV event in 
patients treated with an NSAID, the lowest effective dose should be used for the 
shortest duration possible. Physicians and patients should remain alert for the 
development of such events, even in the absence of previous CV symptoms. 
Patients should be informed about the signs and/or symptoms of serious CV events 
and the steps to take if they occur. </paragraph>
                  <paragraph>Two large, controlled, clinical trials of a COX-2 selective NSAID for the 
treatment of pain in the first 10-14 days following CABG surgery found an 
increased incidence of myocardial infarction and stroke [<content styleCode="italics">see 
<linkHtml href="#section-"> Contraindications (4.2)</linkHtml>]. </content>
                  </paragraph>
                  <paragraph>There is no consistent evidence that concurrent use of aspirin mitigates the 
increased risk of serious CV thrombotic events associated with NSAID use. The 
concurrent use of aspirin and an NSAID does increase the risk of serious GI 
events [<content styleCode="italics">see <linkHtml href="#section-"> Warnings and Precautions 
(5.2)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.2 Gastrointestinal (GI) Effects - Risk of GI Ulceration, 
Bleeding, and Perforation</content>
                  <paragraph>
                     <linkHtml href="#section-"/>NSAIDs, including meloxicam tablets, can cause serious 
gastrointestinal (GI) adverse events including inflammation, bleeding, 
ulceration, and perforation of the stomach, small intestine, or large intestine, 
which can be fatal. These serious adverse events can occur at any time, with or 
without warning symptoms, in patients treated with NSAIDs. Only one in five 
patients who develop a serious upper GI adverse event on NSAID therapy is 
symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs, 
occur in approximately 1% of patients treated for 3 to 6 months, and in about 2 
to 4% of patients treated for one year. These trends continue with longer 
duration of use, increasing the likelihood of developing a serious GI event at 
some time during the course of therapy<content styleCode="italics">. </content>However, even 
short-term therapy is not without risk. </paragraph>
                  <paragraph>Prescribe NSAIDS, including meloxicam tablets, with extreme caution in those 
with a prior history of ulcer disease or gastrointestinal bleeding. Patients 
with a prior history of peptic ulcer disease and/or gastrointestinal bleeding 
who use NSAIDs have a greater than 10-fold increased risk for developing a GI 
bleed compared to patients with neither of these risk factors. Other factors 
that increase the risk for GI bleeding in patients treated with NSAIDs include 
concomitant use of oral corticosteroids or anticoagulants, longer duration of 
NSAID therapy, smoking, use of alcohol, older age, and poor general health 
status. Most spontaneous reports of fatal GI events are in elderly or 
debilitated patients and therefore, special care should be taken in treating 
this population. </paragraph>
                  <paragraph>To minimize the potential risk for an adverse GI event in patients treated 
with an NSAID, use the lowest effective dose for the shortest possible duration. 
Patients and physicians should remain alert for signs and symptoms of GI 
ulceration and bleeding during meloxicam therapy and promptly initiate 
additional evaluation and treatment if a serious GI adverse event is suspected. 
This should include discontinuation of meloxicam until a serious GI adverse 
event is ruled out. For high-risk patients, consider alternate therapies that do 
not involve NSAIDs. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.3 Hepatic Effects</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Borderline elevations of one or more liver tests may occur 
in up to 15% of patients taking NSAIDs including meloxicam tablets. These 
laboratory abnormalities may progress, may remain unchanged, or may be transient 
with continuing therapy. Notable elevations of ALT or AST (approximately three 
or more times the upper limit of normal) have been reported in approximately 1% 
of patients in clinical trials with NSAIDs. In addition, rare cases of severe 
hepatic reactions, including jaundice and fatal fulminant hepatitis, liver 
necrosis and hepatic failure, some of them with fatal outcomes have been 
reported [<content styleCode="italics">see <linkHtml href="#section-"> Adverse Reactions (6.1)</linkHtml>]. 
</content>
                  </paragraph>
                  <paragraph>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom 
an abnormal liver test has occurred, should be evaluated for evidence of the 
development of a more severe hepatic reaction while on therapy with meloxicam. 
If clinical signs and symptoms consistent with liver disease develop, or if 
systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue 
meloxicam [<content styleCode="italics">see <linkHtml href="#section-"> Use in Specific Populations 
(8.6)</linkHtml> and <linkHtml href="#section-"> Clinical Pharmacology (12.3)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.4 Hypertension</content>
                  <paragraph>
                     <linkHtml href="#section-"/>NSAIDs, including meloxicam tablets, can lead to onset of 
new hypertension or worsening of pre-existing hypertension, either of which may 
contribute to the increased incidence of CV events. NSAIDs, including meloxicam 
tablets, should be used with caution in patients with hypertension. Blood 
pressure (BP) should be monitored closely during the initiation of NSAID 
treatment and throughout the course of therapy. </paragraph>
                  <paragraph>Patients taking ACE inhibitors, thiazides or loop diuretics may have impaired 
response to these therapies when taking NSAIDS. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.5 Congestive Heart Failure and Edema</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Fluid retention and edema have been observed in some 
patients taking NSAIDs. Use meloxicam with caution in patients with fluid 
retention, hypertension, or heart failure. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.6 Renal Effects</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Long-term administration of NSAIDs, including meloxicam 
tablets, can result in renal papillary necrosis, renal insufficiency, acute 
renal failure, and other renal injury. Renal toxicity has also been seen in 
patients in whom renal prostaglandins have a compensatory role in the 
maintenance of renal perfusion. In these patients, administration of a 
nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in 
prostaglandin formation and, secondarily, in renal blood flow, which may 
precipitate overt renal decompensation. Patients at greatest risk of this 
reaction are those with impaired renal function, heart failure, liver 
dysfunction, those taking diuretics, ACE-inhibitors, and angiotensin II receptor 
antagonists, and the elderly. Discontinuation of NSAID therapy is usually 
followed by recovery to the pretreatment state. </paragraph>
                  <paragraph>A pharmacokinetic study in patients with mild and moderate renal impairment 
revealed that no dosage adjustments in these patient populations are required. 
Patients with severe renal impairment have not been studied. The use of 
meloxicam in patients with severe renal impairment with CrCl less than 20 mL/min 
is not recommended. A study performed in patients on hemodialysis revealed that 
although overall C<sub>max</sub> was diminished in this population, 
the proportion of free drug not bound to plasma was increased. Therefore it is 
recommended that meloxicam dosage in this population not exceed 7.5 mg per day. 
Closely monitor the renal function of patients with impaired renal function who 
are taking meloxicam. [<content styleCode="italics">see <linkHtml href="#section-"> Dosage and 
Administration (2.1)</linkHtml>, <linkHtml href="#section-"> Use in Specific Populations (8.7)</linkHtml> 
and <linkHtml href="#section-"> Clinical Pharmacology (12.3)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>Use caution when initiating treatment with meloxicam in patients with 
considerable dehydration. It is advisable to rehydrate patients first and then 
start therapy with meloxicam. Caution is also recommended in patients with 
pre-existing kidney disease. </paragraph>
                  <paragraph>The extent to which metabolites may accumulate in patients with renal 
impairment has not been studied with meloxicam. Because some meloxicam 
metabolites are excreted by the kidney, monitor patients with significant renal 
impairment closely. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.7 Anaphylactoid Reactions</content>
                  <paragraph>
                     <linkHtml href="#section-"/>As with other NSAIDS, anaphylactoid reactions have occurred 
in patients without known prior exposure to meloxicam. Meloxicam should not be 
given to patients with the aspirin triad. This symptom complex typically occurs 
in asthmatic patients who experience rhinitis with or without nasal polyps, or 
who exhibit severe, potentially fatal bronchospasm after taking aspirin or other 
NSAIDs [<content styleCode="italics">see <linkHtml href="#section-"> Contraindications (4.1)</linkHtml> and 
<linkHtml href="#section-"> Warnings and Precautions (5.12)</linkHtml>]. </content>Seek emergency help 
in cases where an anaphylactoid reaction occurs. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.8 Adverse Skin Reactions</content>
                  <paragraph>
                     <linkHtml href="#section-"/>NSAIDs, including meloxicam tablets, can cause serious skin 
adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), 
and toxic epidermal necrolysis (TEN), which can be fatal. These serious events 
may occur without warning. Inform patients about the signs and symptoms of 
serious skin manifestations and discontinue use of the drug at the first 
appearance of skin rash or any other sign of hypersensitivity. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.9 .Pregnancy</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Starting at 30 weeks gestation, avoid the use of meloxicam, 
because it may cause premature closure of the ductus arteriosus [<content styleCode="italics">see <linkHtml href="#section-"> Use in Specific Populations (8.1)</linkHtml> and <linkHtml href="#section-"> Patient Counseling Information (17.8)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.10 Corticosteroid Treatment</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Meloxicam cannot be expected to substitute for 
corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation 
of corticosteroids may lead to disease exacerbation. Slowly taper patients on 
prolonged corticosteroid therapy if a decision is made to discontinue 
corticosteroids. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.11 Masking of Inflammation and Fever</content>
                  <paragraph>
                     <linkHtml href="#section-"/>The pharmacological activity of meloxicam in reducing fever 
and inflammation may diminish the utility of these diagnostic signs in detecting 
complications of presumed noninfectious, painful conditions. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.12 Hematological Effects</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Anemia may occur in patients receiving NSAIDs, including 
meloxicam tablets. This may be due to fluid retention, occult or gross GI blood 
loss, or an incompletely described effect upon erythropoiesis. Patients on 
long-term treatment with NSAIDs, including meloxicam, should have their 
hemoglobin or hematocrit checked if they exhibit any signs or symptoms of 
anemia. </paragraph>
                  <paragraph>NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding 
time in some patients. Unlike aspirin, their effect on platelet function is 
quantitatively less, of shorter duration, and reversible. Carefully monitor 
patients treated with meloxicam who may be adversely affected by alterations in 
platelet function, such as those with coagulation disorders or patients 
receiving anticoagulants. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.13 Use in Patients with Pre-existing Asthma</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Patients with asthma may have aspirin-sensitive asthma. The 
use of aspirin in patients with aspirin-sensitive asthma has been associated 
with severe bronchospasm, which can be fatal. Since cross reactivity, including 
bronchospasm, between aspirin and other NSAIDs has been reported in such 
aspirin-sensitive patients, meloxicam should not be administered to patients 
with this form of aspirin sensitivity and should be used with caution in 
patients with pre-existing asthma. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>5.14 Monitoring</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Because serious GI tract ulcerations and bleeding can occur 
without warning symptoms, physicians should monitor for signs or symptoms of GI 
bleeding. Patients on long-term treatment with NSAIDs should have their CBC and 
a chemistry profile checked periodically. If clinical signs and symptoms 
consistent with liver or renal disease develop, systemic manifestations occur 
(e.g., eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, 
meloxicam should be discontinued.</paragraph>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="a588c239-76ad-42b4-807f-3662eb8fb0db"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6. ADVERSE REACTIONS</title>
               <text>
                  <paragraph>
                     <linkHtml href="#section-"/>Because clinical trials are conducted under widely varying 
conditions, adverse reaction rates observed in the clinical trials of a drug 
cannot be directly compared to rates in the clinical trials of another drug and 
may not reflect the rates observed in practice. </paragraph>
                  <paragraph>The following serious adverse reactions are discussed elsewhere in the 
labeling: </paragraph>
                  <list listType="unordered" ID="i7f6b6bdc-44b9-4234-8da3-831750a7b4a8">
                     <item>Cardiovascular thrombotic events [<content styleCode="italics">see <linkHtml href="#section-">      Boxed Warning </linkHtml>and <linkHtml href="#section-">      Warnings and Precautions 
(5.1)</linkHtml>] </content>
                     </item>
                     <item>Gastrointestinal effects â€“ risk of GI ulceration, bleeding, and perforation 
<content styleCode="italics">[see <linkHtml href="#section-">      Boxed Warning</linkHtml> and <linkHtml href="#section-">      Warnings and Precautions (5.2)</linkHtml>] </content>
                     </item>
                     <item>Hepatic effects [see <linkHtml href="#section-">      Warnings and Precautions (5.3)</linkHtml>] 
</item>
                     <item>Hypertension [see <linkHtml href="#section-">      Warnings and Precautions (5.4)</linkHtml>] 
</item>
                     <item>Congestive heart failure and edema [see <linkHtml href="#section-">      Warnings and 
Precautions (5.5)</linkHtml>] 
</item>
                     <item>Renal effects [see <linkHtml href="#section-">      Warnings and Precautions (5.6)</linkHtml>] 
</item>
                     <item>Anaphylactoid reactions [see <linkHtml href="#section-">      Warnings and Precautions 
(5.7)</linkHtml>] 
</item>
                     <item>Adverse skin reactions [see <linkHtml href="#section-">      Warnings and Precautions 
(5.8)</linkHtml>] </item>
                  </list>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>6.1 Clinical Trials Experience<linkHtml href="#section-"/>
                     <linkHtml href="#section-"/>
                     <linkHtml href="#section-"/>Adults</content>
                  <paragraph>
                     <linkHtml href="#section-"/>
                     <content styleCode="underline">Osteoarthritis and Rheumatoid 
Arthritis </content>
                  </paragraph>
                  <paragraph>The meloxicam Phase 2/3 clinical trial database includes 10,122 OA patients 
and 1012 RA patients treated with meloxicam 7.5 mg/day, 3,505 OA patients and 
1351 RA patients treated with meloxicam 15 mg/day. Meloxicam at these doses was 
administered to 661 patients for at least 6 months and to 312 patients for at 
least one year. Approximately 10,500 of these patients were treated in ten 
placebo- and/or active-controlled osteoarthritis trials and 2363 of these 
patients were treated in ten placebo- and/or active-controlled rheumatoid 
arthritis trials. Gastrointestinal (GI) adverse events were the most frequently 
reported adverse events in all treatment groups across meloxicam trials. </paragraph>
                  <paragraph>A 12-week multicenter, double-blind, randomized trial was conducted in 
patients with osteoarthritis of the knee or hip to compare the efficacy and 
safety of meloxicam with placebo and with an active control. Two 12-week 
multicenter, double-blind, randomized trials were conducted in patients with 
rheumatoid arthritis to compare the efficacy and safety of meloxicam with 
placebo. </paragraph>
                  <paragraph>Table 1a depicts adverse events that occurred in â‰¥2% of the meloxicam 
treatment groups in a 12-week placebo- and active-controlled osteoarthritis 
trial.</paragraph>
                  <paragraph>Table 1b depicts adverse events that occurred in â‰¥2% of the meloxicam 
treatment groups in two 12-week placebo- controlled rheumatoid arthritis trials.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Table 1a Adverse Events (%) Occurring in â‰¥ 2% of Meloxicam Patients in a 12-Week 
Osteoarthritis Placebo- and Active-Controlled Trial</content>
                  </paragraph>
                  <paragraph>
                     <br/>
                     <content styleCode="bold"/>
                  </paragraph>
                  <table ID="i12e85f8b-0e77-44c0-8476-c5d26e28414d" border="0" cellpadding="0" cellspacing="0" width="1184">
                     <col width="263"/>
                     <col width="11"/>
                     <col width="178"/>
                     <col width="10"/>
                     <col width="184"/>
                     <col width="9"/>
                     <col width="178"/>
                     <col width="10"/>
                     <col width="161"/>
                     <tbody>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>Â Placebo</td>
                           <td>
                              <br/>
                           </td>
                           <td>Meloxicam 7.5 mg daily</td>
                           <td>
                              <br/>
                           </td>
                           <td>Meloxicam 15 mg daily</td>
                           <td>
                              <br/>
                           </td>
                           <td>Diclofenac 100 mg daily</td>
                        </tr>
                        <tr>
                           <td>No. of Patients</td>
                           <td>
                              <br/>
                           </td>
                           <td>157</td>
                           <td>
                              <br/>
                           </td>
                           <td>154</td>
                           <td>
                              <br/>
                           </td>
                           <td>156</td>
                           <td>
                              <br/>
                           </td>
                           <td>153</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Gastrointestinal</td>
                           <td>
                              <br/>
                           </td>
                           <td>17.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>20.1</td>
                           <td>
                              <br/>
                           </td>
                           <td>17.3</td>
                           <td>
                              <br/>
                           </td>
                           <td>28.1</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Abdominal Pain</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.3</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Diarrhea</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>7.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>9.2</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Dyspepsia</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>6.5</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Flatulence</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.9</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Nausea</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>7.2</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Body as a Whole</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Accident household</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>EdemaÂ¹</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.3</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Fall</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.3</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Influenza-like symptoms</td>
                           <td>
                              <br/>
                           </td>
                           <td>5.1</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>5.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Central and Peripheral Nervous System</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Dizziness</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.0</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Headache</td>
                           <td>
                              <br/>
                           </td>
                           <td>10.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>7.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>8.3</td>
                           <td>
                              <br/>
                           </td>
                           <td>5.9</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Respiratory</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Pharyngitis</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.3</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.3</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Upper respiratory tract infection</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.3</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Skin</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>RashÂ²</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.0</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Â¹ WHO preferred terms edema, edema dependent, edema peripheral, and edema legs combined</paragraph>
                  <paragraph>Â² WHO preferred terms rash, rash erythematous, and rash maculo-papular combined<content styleCode="bold">Â Â Â Â Â Â Â   <br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="b2c71d31-30b8-4d7c-aaca-380746a569b0"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>Table 1b Adverse Events (%) Occurring in â‰¥2% of Meloxicam Patients in two 12-Week Rheumatoid Arthritis Placebo- Controlled Trials</title>
               <text>
                  <table ID="ic0b3a86a-c788-4170-8927-c8617d25612e" border="0" cellpadding="0" cellspacing="0" width="991">
                     <col width="424"/>
                     <col width="8"/>
                     <col width="178"/>
                     <col width="10"/>
                     <col width="184"/>
                     <col width="9"/>
                     <col width="178"/>
                     <tbody>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>Placebo</td>
                           <td>
                              <br/>
                           </td>
                           <td>Meloxicam 7.5 mg daily</td>
                           <td>
                              <br/>
                           </td>
                           <td>Meloxicam 15 mg daily</td>
                        </tr>
                        <tr>
                           <td>No. of Patients</td>
                           <td>
                              <br/>
                           </td>
                           <td>469</td>
                           <td>
                              <br/>
                           </td>
                           <td>481</td>
                           <td>
                              <br/>
                           </td>
                           <td>477</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Gastrointestinal Disorders</td>
                           <td>
                              <br/>
                           </td>
                           <td>14.1</td>
                           <td>
                              <br/>
                           </td>
                           <td>18.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>16.8</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Abdominal pain NOSÂ²</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.3</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Dyspeptic signs and symptomsÂ¹</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>5.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.0</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>NauseaÂ²</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.3</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.8</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>General Disorders and Administration Site
  Conditions</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Influenza-like illnessÂ²</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.1</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.3</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Infection and Infestations</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Upper Respiratory tract infections-pathogen class unspecifiedÂ¹</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.1</td>
                           <td>
                              <br/>
                           </td>
                           <td>7.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>6.5</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Musculoskeletal and Connective Tissue
  Disorders</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Joint related signs and symptomsÂ¹</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.3</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Nervous System Disorders</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Headaches NOSÂ²</td>
                           <td>
                              <br/>
                           </td>
                           <td>6.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>6.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>5.5</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Skin and Subcutaneous Tissue Disorders</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Rash NOSÂ²</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.7</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.1</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Â¹ MedDRA high level term (preferred terms): dyspeptic signs and symptoms (dyspepsia, dyspepsia aggravated, eructation, gastrointestinal irritation), upper respiratory tract infections-pathogen unspecified<br/>
                     <br/>Â (laryngitis NOS, pharyngitis NOS, sinusitis NOS), joint related signs and symptoms (arthralgia, arthralgia aggravated, joint crepitation, joint effusion, joint swelling)<br/>
                     <br/>Â² MedDRA preferred term: nausea, abdominal pain NOS, influenza-like illness, headaches NOS, and rash NOS</paragraph>
                  <br/>
                  <paragraph>
                     <br/>
                  </paragraph>The adverse events that occurred with meloxicam in â‰¥2% of patients treated 
short-term (4-6 weeks) and long-term (6 months) in active-controlled 
osteoarthritis trials are presented in Table 2.<br/>
                  <br/>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="43a2e7a4-feb0-4e5c-b9ca-de3c4e57eed4"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>Table 2 Adverse Events (%) Occurring in â‰¥2% of Meloxicam Patients in 4 to 6 Weeks and 6 Month Active-Controlled Osteoarthritis Trials</title>
               <text>
                  <br/>
                  <table ID="i82cbf66e-940e-4582-8017-4382faec5228" border="0" cellpadding="0" cellspacing="0" width="1167">
                     <col width="424"/>
                     <col width="8"/>
                     <col width="178"/>
                     <col width="10"/>
                     <col width="184"/>
                     <col width="14"/>
                     <col width="178"/>
                     <col width="10"/>
                     <col width="161"/>
                     <tbody>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>4 - 6 Weeks Controlled
  Trials</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>6 Month Controlled Trials</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>Meloxicam 7.5 mg daily</td>
                           <td>
                              <br/>
                           </td>
                           <td>Meloxicam 15 mg daily</td>
                           <td>
                              <br/>
                           </td>
                           <td>Meloxicam 7.5 mg daily</td>
                           <td>
                              <br/>
                           </td>
                           <td>Meloxicam 15 mg daily</td>
                        </tr>
                        <tr>
                           <td>No. of Patients</td>
                           <td>
                              <br/>
                           </td>
                           <td>8955</td>
                           <td>
                              <br/>
                           </td>
                           <td>256</td>
                           <td>
                              <br/>
                           </td>
                           <td>169</td>
                           <td>
                              <br/>
                           </td>
                           <td>306</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Gastrointestinal</td>
                           <td>
                              <br/>
                           </td>
                           <td>11.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>18.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>26.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>24.2</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Abdominal pain</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.7</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.3</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.7</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.9</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Constipation</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Diarrhea</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.7</td>
                           <td>
                              <br/>
                           </td>
                           <td>5.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Dyspepsia</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>7.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>8.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>9.5</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Flatulence</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Nausea</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.7</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.7</td>
                           <td>
                              <br/>
                           </td>
                           <td>7.2</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Vomiting</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Body as a Whole</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Accident household</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.9</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>EdemaÂ¹</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.6</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Pain</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.9</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>5.2</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â </content>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Central and Peripheral Nervous System</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Dizziness</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.1</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Headache</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.7</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.6</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Hematologic</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Anemia</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.1</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.1</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.9</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Musculoskeletal</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Arthralgia</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>5.3</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.3</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Back pain</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.5</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.7</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Psychiatric</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Insomnia</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.6</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.6</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Respiratory</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Coughing</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.8</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.0</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Upper respiratory tract infection</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>8.3</td>
                           <td>
                              <br/>
                           </td>
                           <td>7.5</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Skin</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Pruritus</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.0</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>RashÂ²</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.3</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.2</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.0</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.3</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Urinary</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Micturition frequency</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.1</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.3</td>
                        </tr>
                        <tr>
                           <td>
                              <content>Â 
  </content>Urinary tract infection</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.3</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.4</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.7</td>
                           <td>
                              <br/>
                           </td>
                           <td>6.9</td>
                        </tr>
                     </tbody>
                  </table>Â¹ WHO preferred terms edema, edema dependent, edema peripheral, and edema legs combined<br/>Â² WHO preferred terms rash, rash erythematous, and rash maculo-papular combined<br/>
                  <paragraph>
                     <linkHtml href="#section-"/>Higher doses of meloxicam (22.5 mg and greater) have been 
associated with an increased risk of serious GI events; therefore, the daily 
dose of meloxicam should not exceed 15 mg. </paragraph>
                  <paragraph>The following is a list of adverse drug reactions occurring in less than 2% of 
patients receiving meloxicam in clinical trials involving approximately 16,200 
patients.</paragraph>
                  <linkHtml href="#section-"/>
                  <table ID="i2df306eb-2d17-43e4-8536-7f320a63b6bc" width="100%">
                     <col width="32%"/>
                     <col width="68%"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">BodyÂ </content>
                              <content styleCode="bold">asÂ </content>
                              <content styleCode="bold">aÂ </content>
                              <content styleCode="bold">Whole</content>
                              <br/>
                           </td>
                           <td>allergicÂ reaction,Â faceÂ edema,Â fatigue,Â fever,Â hotÂ flushes,Â malaise,Â syncope,Â weightÂ decrease,Â weightÂ increase<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Cardiovascular</content>
                              <br/>
                           </td>
                           <td>anginaÂ pectoris,Â cardiacÂ failure,Â hypertension,Â hypotension,Â myocardialÂ infarction,Â vasculitis<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">CentralÂ </content>
                              <content styleCode="bold">andÂ </content>
                              <content styleCode="bold">PeripheralÂ </content>
                              <content styleCode="bold">NervousÂ </content>
                              <content styleCode="bold">System</content>
                              <br/>
                           </td>
                           <td>convulsions,Â paresthesia,Â tremor,Â vertigo<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Gastrointestinal</content>
                              <br/>
                           </td>
                           <td>colitis,Â dryÂ mouth,Â duodenalÂ ulcer,Â eructation,Â esophagitis,Â gastricÂ ulcer,Â gastritis,Â gastroesophagealÂ reflux,Â gastrointestinalÂ hemorrhage,Â hematemesis,Â hemorrhagicÂ duodenalÂ ulcer,Â hemorrhagicÂ gastricÂ ulcer,Â intestinalÂ perforation,Â melena,Â pancreatitis,Â perforatedÂ duodenalÂ ulcer,Â perforatedÂ gastricÂ ulcer,Â stomatitisÂ ulcerative<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">HeartÂ </content>
                              <content styleCode="bold">RateÂ </content>
                              <content styleCode="bold">andÂ </content>
                              <content styleCode="bold">Rhythm</content>
                              <br/>
                           </td>
                           <td>arrhythmia,Â palpitation,Â tachycardia<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Hematologic</content>
                              <br/>
                           </td>
                           <td>leukopenia,Â purpura,Â thrombocytopenia<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">LiverÂ </content>
                              <content styleCode="bold">andÂ </content>
                              <content styleCode="bold">BiliaryÂ </content>
                              <content styleCode="bold">System</content>
                              <br/>
                           </td>
                           <td>ALTÂ increased,Â ASTÂ increased,Â bilirubinemia,Â GGTÂ increased,Â hepatitis<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">MetabolicÂ </content>
                              <content styleCode="bold">andÂ </content>
                              <content styleCode="bold">Nutritional</content>
                              <br/>
                           </td>
                           <td>dehydration<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Psychiatric</content>
                              <br/>
                           </td>
                           <td>abnormalÂ dreaming,Â anxiety,Â appetiteÂ increased,Â confusion,Â depression,Â nervousness,Â somnolence<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Respiratory</content>
                              <br/>
                           </td>
                           <td>asthma,Â bronchospasm,Â dyspnea<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">SkinÂ </content>
                              <content styleCode="bold">andÂ </content>
                              <content styleCode="bold">Appendages</content>
                              <br/>
                           </td>
                           <td>alopecia,Â angioedema,Â bullousÂ eruption,Â photosensitivityÂ reaction,Â pruritus,Â sweatingÂ increased,Â urticaria<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">SpecialÂ </content>
                              <content styleCode="bold">Senses</content>
                              <br/>
                           </td>
                           <td>abnormalÂ vision,Â conjunctivitis,Â tasteÂ perversion,Â tinnitus<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">UrinaryÂ </content>
                              <content styleCode="bold">System</content>
                              <br/>
                           </td>
                           <td>albuminuria,Â BUNÂ increased,Â creatinineÂ increased,Â hematuria,Â renalÂ failure<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>6.2 Post Marketing Experience<paragraph>
                     <linkHtml href="#section-"/>The following adverse reactions have been identified during 
post approval use of meloxicam. Because these reactions are reported voluntarily 
from a population of uncertain size, it is not always possible to reliably 
estimate their frequency or establish a causal relationship to drug exposure. 
Decisions about whether to include an adverse event from spontaneous reports in 
labeling are typically based on one or more of the following factors: (1) 
seriousness of the event, (2) number of reports, or (3) strength of causal 
relationship to the drug. Adverse reactions reported in worldwide post marketing 
experience or the literature include: acute urinary retention; agranulocytosis; 
alterations in mood (such as mood elevation); anaphylactoid reactions including 
shock; erythema multiforme; exfoliative dermatitis; interstitial nephritis; 
jaundice; liver failure; Stevens-Johnson syndrome, and toxic epidermal 
necrolysis.</paragraph>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3664c866-467e-4f17-80bd-c00f6b49ff0d"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7. DRUG INTERACTIONS</title>
               <text>
                  <paragraph>
                     <linkHtml href="#section-"/>See also <linkHtml href="#section-"> Clinical Pharmacology (12.3)</linkHtml>. 
</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>7.1 ACE-inhibitors</content>
                  <paragraph>
                     <linkHtml href="#section-"/>NSAIDs may diminish the antihypertensive effect of 
ACE-inhibitors. This interaction should be given consideration in patients 
taking meloxicam concomitantly with ACE-inhibitors. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>7.2 Aspirin</content>
                  <paragraph>
                     <linkHtml href="#section-"/>When meloxicam is administered with aspirin (1000 mg three 
times daily) to healthy volunteers, an increase the AUC (10%) and C<sub>max</sub> (24%) of meloxicam was noted. The clinical significance of 
this interaction is not known; however, as with other NSAIDs concomitant 
administration of meloxicam and aspirin is not generally recommended because of 
the potential for increased adverse effects. </paragraph>
                  <paragraph>Concomitant administration of low-dose aspirin with meloxicam may result in 
an increased rate of GI ulceration or other complications, compared to use of 
meloxicam alone. Meloxicam is not a substitute for aspirin for cardiovascular 
prophylaxis. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>7.3 Diuretics</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Clinical studies, as well as post marketing observations, 
have shown that NSAIDs can reduce the natriuretic effect of furosemide and 
thiazides in some patients. This response has been attributed to inhibition of 
renal prostaglandin synthesis. However, studies with furosemide agents and 
meloxicam have not demonstrated a reduction in natriuretic effect. Furosemide 
single and multiple dose pharmacodynamics and pharmacokinetics are not affected 
by multiple doses of meloxicam. Nevertheless, during concomitant therapy with 
meloxicam, patients should be observed closely for signs of renal failure [<content styleCode="italics">see <linkHtml href="#section-"> Warnings and Precautions (5.6)</linkHtml>], </content>as 
well as to ensure diuretic efficacy. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>7.4 Lithium</content>
                  <paragraph>
                     <linkHtml href="#section-"/>In a study conducted in healthy subjects, mean pre-dose 
lithium concentration and AUC were increased by 21% in subjects receiving 
lithium doses ranging from 804 to 1072 mg twice daily with meloxicam 15 mg every 
day as compared to subjects receiving lithium alone. These effects have been 
attributed to inhibition of renal prostaglandin synthesis by meloxicam. Closely 
monitor patients on lithium treatment for signs of lithium toxicity when 
meloxicam is introduced, adjusted, or withdrawn. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>7.5 Methotrexate</content>
                  <paragraph>
                     <linkHtml href="#section-"/>NSAIDs have been reported to competitively inhibit 
methotrexate accumulation in rabbit kidney slices. Therefore, NSAIDs may reduce 
the elimination of methotrexate , thereby enhancing the toxicity of 
methotrexate. Use caution when meloxicam is administered concomitantly with 
methotrexate [<content styleCode="italics">see <linkHtml href="#section-"> Clinical Pharmacology 
(12.3)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>7.6 Cyclosporine</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Meloxicam, like other NSAIDs, may affect renal 
prostaglandins, thereby altering the renal toxicity of certain drugs. Therefore, 
concomitant therapy with meloxicam may increase cyclosporine's nephrotoxicity. 
Use caution when meloxicam is administered concomitantly with cyclosporine. 
</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>7.7 Warfarin</content>
                  <paragraph>
                     <linkHtml href="#section-"/>The effects of warfarin and NSAIDs on GI bleeding are 
synergistic, such that users of both drugs together have a risk of serious GI 
bleeding higher than users of either drug alone. </paragraph>
                  <paragraph>Monitor anticoagulant activity, particularly in the first few days after 
initiating or changing meloxicam therapy in patients receiving warfarin or 
similar agents, since these patients are at an increased risk of bleeding than 
with the use of either drug alone. Use caution when administering meloxicam with 
warfarin since patients on warfarin may experience changes in INR and an 
increased risk of bleeding complications when a new medication is introduced 
[<content styleCode="italics">see <linkHtml href="#section-"> Clinical Pharmacology (12.3)</linkHtml>]. 
</content>
                  </paragraph>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="268bd505-1ffa-4e9f-b27c-d186851036e5"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8. USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>8.1 Pregnancy</content>
                  <linkHtml href="#section-"/>
                  <br/>
                  <br/>Pregnancy Category C; Category D starting 30 weeks 
gestation<paragraph>
                     <linkHtml href="#section-"/>There are no adequate and well-controlled studies in 
pregnant women. Meloxicam crosses the placental barrier. Prior to 30 weeks 
gestation, use meloxicam during pregnancy only if the potential benefit 
justifies the potential risk to the fetus. Starting at 30 weeks gestation, avoid 
meloxicam and other NSAIDs, in pregnant women as premature closure of the ductus 
arteriosus in the fetus may occur. If this drug is used during this time period 
in pregnancy, inform the patient of the potential hazard to a fetus [<content styleCode="italics">see <linkHtml href="#section-"> Warnings and Precautions (5.9)</linkHtml> and <linkHtml href="#section-"> Patient Counseling Information (17.8)</linkHtml>]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Teratogenic Effects</content>
                  </paragraph>
                  <paragraph>Meloxicam was not teratogenic when administered to pregnant rats during fetal 
organogenesis at oral doses up to 4 mg/kg/day (2.6-fold greater than the maximum 
recommended human daily dose [MRHD] based on body surface area [BSA] 
comparison). Administration of meloxicam to pregnant rabbits throughout 
embryogenesis produced an increased incidence of septal defects of the heart at 
an oral dose of 60 mg/kg/day. The no effect level was 20 mg/kg/day (26-fold 
greater than the MRHD based on BSA conversion). </paragraph>
                  <paragraph>
                     <content styleCode="italics">Nonteratogenic Effects</content>
                  </paragraph>
                  <paragraph>In rats and rabbits, embryolethality occurred at oral meloxicam doses of 1 
mg/kg/day and 5 mg/kg/day, respectively (0.65-and 6.5-fold greater, 
respectively, than the MRHD based on BSA comparison) when administered 
throughout organogenesis.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>8.2 Labor and Delivery</content>
                  <paragraph>
                     <linkHtml href="#section-"/>The effects of meloxicam on labor and delivery of pregnant 
women are unknown. Oral administration of meloxicam to pregnant rats during late 
gestation through lactation increased the incidence of dystocia, delayed 
parturition, and decreased offspring survival at meloxicam doses of 0.125 
mg/kg/day or greater (at least 12.5 times lower than the maximum recommended 
human daily dose based on body surface area comparison). </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>8.3 Nursing Mothers</content>
                  <paragraph>
                     <linkHtml href="#section-"/>It is not known whether this drug is excreted in human 
milk; however, meloxicam was excreted in the milk of lactating rats at 
concentrations higher than those in plasma. Because many drugs are excreted in 
human milk and because of the potential for serious adverse reactions in nursing 
infants from meloxicam a decision should be made whether to discontinue nursing 
or to discontinue the drug, taking into account the importance of the drug to 
the mother. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>8.4 Pediatric Use</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Use of this drug for a pediatric indication is protected by 
marketing exclusivity.</paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>8.5 Geriatric Use</content>
                  <paragraph>
                     <linkHtml href="#section-"/>As with any NSAID, caution should be exercised in treating 
the elderly (65 years and older). </paragraph>
                  <paragraph>Of the total number of subjects in clinical studies, 5157 were age 65 and 
over (4044 in OA studies and 1113 in RA studies). No overall differences in 
safety or effectiveness were observed between these subjects and younger 
subjects, and other reported clinical experience has not identified differences 
in responses between the elderly and younger patients, but greater sensitivity 
of some older individuals cannot be ruled out. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>8.6 Hepatic Impairment</content>
                  <paragraph>
                     <linkHtml href="#section-"/>No dose adjustment is necessary in patients with mild to 
moderate hepatic impairment. Patients with severe hepatic impairment have not 
been adequately studied. Since meloxicam is significantly metabolized in the 
liver, the use of meloxicam in these patients should be done with caution [<content styleCode="italics">see <linkHtml href="#section-"> Warnings and Precautions (5.3)</linkHtml> and <linkHtml href="#section-"> Clinical Pharmacology (12.3)</linkHtml>] </content>
                  </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>8.7 Renal Impairment</content>
                  <paragraph>
                     <linkHtml href="#section-"/>No dose adjustment is necessary in patients with mild to 
moderate renal impairment. Patients with severe renal impairment have not been 
studied. The use of meloxicam in subjects with severe renal impairment is not 
recommended. Following a single dose of meloxicam, the free C<sub>max</sub> plasma concentrations were higher in patients with renal 
failure on chronic hemodialysis (1% free fraction) in comparison to healthy 
volunteers (0.3% free fraction). Therefore it is recommended that meloxicam 
dosage in this population not exceed 7.5 mg per day Hemodialysis did not lower 
the total drug concentration in plasma; therefore, additional doses are not 
necessary after hemodialysis. Meloxicam is not dialyzable. [<content styleCode="italics">see <linkHtml href="#section-"> Dosage and Administration (2.1)</linkHtml>, <linkHtml href="#section-"> Warnings and Precautions (5.6)</linkHtml> and <linkHtml href="#section-"> Clinical 
Pharmacology (12.3)</linkHtml>]. </content>
                  </paragraph>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="5f617011-c7b0-4bdf-bf0c-2513993c5cdc"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10. OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <linkHtml href=""/>There is limited experience with meloxicam overdose. Four 
cases have taken 6 to 11 times the highest recommended dose; all recovered. 
Cholestyramine is known to accelerate the clearance of meloxicam. </paragraph>
                  <paragraph>Symptoms following acute NSAID overdose include lethargy, drowsiness, nausea, 
vomiting, and epigastric pain, which are generally reversible with supportive 
care. Gastrointestinal bleeding can occur. Severe poisoning may result in 
hypertension, acute renal failure, hepatic dysfunction, respiratory depression, 
coma, convulsions, cardiovascular collapse, and cardiac arrest. Anaphylactoid 
reactions have been reported with therapeutic ingestion of NSAIDs, and may occur 
following an overdose. </paragraph>
                  <paragraph>Patients should be managed with symptomatic and supportive care following an 
NSAID overdose. Administration of activated charcoal is recommended for patients 
who present 1-2 hours after overdose. For substantial overdose or severely 
symptomatic patients, activated charcoal may be administered repeatedly. 
Accelerated removal of meloxicam by 4 gm oral doses of cholestyramine given 
three times a day was demonstrated in a clinical trial. Administration of 
cholestyramine may be useful following an overdose. Forced diuresis, 
alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to 
high protein binding. </paragraph>
                  <paragraph>For additional information about overdose treatment, call a poison control 
center (1-800-222-1222). </paragraph>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="6c97824f-c17f-492b-8a85-8651d120f53d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11. DESCRIPTION</title>
               <text>
                  <paragraph>
                     <linkHtml href="#section-"/>Meloxicam, an oxicam derivative, is a member of the enolic 
acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet 
contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is 
chemically designated as 4-hydroxy-2-methyl-<content styleCode="italics">N</content>-(5-methyl-2-thiazolyl)-<content styleCode="italics">2H</content>-1,2-benzothiazine-3carboxamide-1,1-dioxide. The 
molecular weight is 351.4. Its empirical formula is C<sub>14</sub>H<sub>13</sub>N<sub>3</sub>O<sub>4</sub>S<sub>2</sub> and it has the following structural 
formula.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <linkHtml href="#section-"/>Meloxicam is a pastel yellow solid, practically insoluble 
in water, with higher solubility observed in strong acids and bases. It is very 
slightly soluble in methanol. Meloxicam has an apparent partition coefficient 
(log P)<sub>app</sub> = 0.1 in <content styleCode="italics">n</content>-octanol/buffer pH 7.4. Meloxicam has pKa values of 1.1 
and 4.2. </paragraph>
                  <paragraph>Meloxicam is available as a tablet for oral administration containing 7.5 mg 
or 15 mg meloxicam. </paragraph>
                  <paragraph>The inactive ingredients in Meloxicam tablets USP include colloidal silicon 
dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline 
cellulose, povidone and sodium citrate dihydrate.</paragraph>
               </text>
               <effectiveTime value="20110908"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM1">
                     <text>Structure Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="MeloxicamStructure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="462cc779-a264-4e46-bc46-de6f18cb9db1"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12. CLINICAL PHARMACOLOGY</title>
               <text>
                  <linkHtml href="#section-"/>
                  <br/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>12.1 Mechanism of Action</content>
                  <paragraph>
                     <linkHtml href="#section-"/>The mechanism of action of meloxicam, like that of other 
NSAIDs, may be related to prostaglandin synthetase (cyclooxygenase) inhibition 
which is involved in the initial steps of the arachidonic acid cascade, 
resulting in the reduced formation of prostaglandins, thromboxanes and 
prostacylin. It is not completely understood how reduced synthesis of these 
compounds results in therapeutic efficacy. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>12.2 Pharmacodynamics</content>
                  <paragraph>
                     <linkHtml href="#section-"/>Meloxicam exhibits anti-inflammatory, analgesic, and 
antipyretic activities. </paragraph>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>12.3 Pharmacokinetics<linkHtml href="#section-"/>
                     <br/>
                     <br/>
                  </content>
                  <br/>Absorption<paragraph>
                     <linkHtml href="#section-"/>The absolute bioavailability of meloxicam capsules was 89% 
following a single oral dose of 30 mg compared with 30 mg IV bolus injection. 
Following single intravenous doses, dose-proportional pharmacokinetics were 
shown in the range of 5 mg to 60 mg. After multiple oral doses the 
pharmacokinetics of meloxicam capsules were dose-proportional over the range of 
7.5 mg to 15 mg. Mean C<sub>max</sub> was achieved within four to 
five hours after a 7.5 mg meloxicam tablet was taken under fasted conditions, 
indicating a prolonged drug absorption. With multiple dosing, steady-state 
concentrations were reached by Day 5. A second meloxicam concentration peak 
occurs around 12 to 14 hours post-dose suggesting biliary recycling.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Table 3 Single Dose and Steady-State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam (Mean and % CV)Â¹</content>
                  </paragraph>
                  <br/>
                  <table border="0" cellpadding="0" cellspacing="0" width="1219" ID="i374f1201-e59f-4fdb-8420-80a9b5d1c677">
                     <col width="234"/>
                     <col width="99"/>
                     <col width="9"/>
                     <col width="135"/>
                     <col width="8"/>
                     <col width="116"/>
                     <col width="8"/>
                     <col width="136"/>
                     <col width="13"/>
                     <col width="224"/>
                     <col width="10"/>
                     <col width="227"/>
                     <tbody>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>Steady State</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>Single Dose</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Pharmacokinetic Parameters (% CV)</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>Healthy male adults</td>
                           <td>
                              <br/>
                           </td>
                           <td>Elderly males</td>
                           <td>
                              <br/>
                           </td>
                           <td>Elderly females</td>
                           <td>
                              <br/>
                           </td>
                           <td>Renal failure (Fasted)</td>
                           <td>
                              <br/>
                           </td>
                           <td>Hepatic insufficiency (Fasted)</td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>(Fed)Â²</td>
                           <td>
                              <br/>
                           </td>
                           <td>(Fed)Â²</td>
                           <td>
                              <br/>
                           </td>
                           <td>(Fed)Â²</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>7.5 mg Â³<content>Â 
  </content>tablets</td>
                           <td>
                              <br/>
                           </td>
                           <td>15 mg capsules</td>
                           <td>
                              <br/>
                           </td>
                           <td>15 mg capsules</td>
                           <td>
                              <br/>
                           </td>
                           <td>15 mg capsules</td>
                           <td>
                              <br/>
                           </td>
                           <td>15 mg capsules</td>
                        </tr>
                        <tr>
                           <td>N</td>
                           <td>
                              <br/>
                           </td>
                           <td>
                              <br/>
                           </td>
                           <td>18</td>
                           <td>
                              <br/>
                           </td>
                           <td>5</td>
                           <td>
                              <br/>
                           </td>
                           <td>8</td>
                           <td>
                              <br/>
                           </td>
                           <td>12</td>
                           <td>
                              <br/>
                           </td>
                           <td>12</td>
                        </tr>
                        <tr>
                           <td>C max</td>
                           <td>[Âµg/mL]</td>
                           <td>
                              <br/>
                           </td>
                           <td>1.05 (20)</td>
                           <td>
                              <br/>
                           </td>
                           <td>2.3 (59)</td>
                           <td>
                              <br/>
                           </td>
                           <td>3.2 (24)</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.59 (36)</td>
                           <td>
                              <br/>
                           </td>
                           <td>0.84 (29)</td>
                        </tr>
                        <tr>
                           <td>t max</td>
                           <td>[h]</td>
                           <td>
                              <br/>
                           </td>
                           <td>4.9 (8)</td>
                           <td>
                              <br/>
                           </td>
                           <td>5 (12)</td>
                           <td>
                              <br/>
                           </td>
                           <td>6 (27)</td>
                           <td>
                              <br/>
                           </td>
                           <td>4 (65)</td>
                           <td>
                              <br/>
                           </td>
                           <td>10 (87)</td>
                        </tr>
                        <tr>
                           <td>t 1/2</td>
                           <td>[h]</td>
                           <td>
                              <br/>
                           </td>
                           <td>20.1 (29)</td>
                           <td>
                              <br/>
                           </td>
                           <td>21 (34)</td>
                           <td>
                              <br/>
                           </td>
                           <td>24 (34)</td>
                           <td>
                              <br/>
                           </td>
                           <td>18 (46)</td>
                           <td>
                              <br/>
                           </td>
                           <td>16 (29)</td>
                        </tr>
                        <tr>
                           <td>CL/f</td>
                           <td>[mL/min]</td>
                           <td>
                              <br/>
                           </td>
                           <td>8.8 (29)</td>
                           <td>
                              <br/>
                           </td>
                           <td>9.9 (76)</td>
                           <td>
                              <br/>
                           </td>
                           <td>5.1 (22)</td>
                           <td>
                              <br/>
                           </td>
                           <td>19 (43)</td>
                           <td>
                              <br/>
                           </td>
                           <td>11 (44)</td>
                        </tr>
                        <tr>
                           <td>Vz/fâ´</td>
                           <td>[L]</td>
                           <td>
                              <br/>
                           </td>
                           <td>14.7 (32)</td>
                           <td>
                              <br/>
                           </td>
                           <td>15 (42)</td>
                           <td>
                              <br/>
                           </td>
                           <td>10 (30)</td>
                           <td>
                              <br/>
                           </td>
                           <td>26 (44)</td>
                           <td>
                              <br/>
                           </td>
                           <td>14 (29)</td>
                        </tr>
                     </tbody>
                  </table>Â¹ The parameter values in the table are from various studies<br/>Â² not under high fat conditions<br/>Â³ Meloxicam tablets<br/>â´ Vz/f = Dose/(AUCâˆ™Kel)<br/>
               </text>
               <effectiveTime value="20110908"/>
               <component>
                  <section>
                     <id root="6d2bd8f7-367d-46a5-9cf3-3710f1bfdbbc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <linkHtml href=""/>Food and Antacid Effects<paragraph>
                           <linkHtml href=""/>Administration of meloxicam capsules following a high fat 
breakfast (75 g of fat) resulted in mean peak drug levels (i.e., C<sub>max</sub>) being increased by approximately 22% while the extent of 
absorption (AUC) was unchanged. The time to maximum concentration (T<sub>max</sub>) was achieved between 5 and 6 hours. No pharmacokinetic 
interaction was detected with concomitant administration of antacids. Based on 
these results, meloxicam can be administered without regard to timing of meals 
or concomitant administration of antacids. </paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Distribution<paragraph>
                           <linkHtml href=""/>The mean volume of distribution (Vss) of meloxicam is 
approximately 10 L. Meloxicam is ~99.4% bound to human plasma proteins 
(primarily albumin) within the therapeutic dose range. The fraction of protein 
binding is independent of drug concentration, over the clinically relevant 
concentration range, but decreases to ~99% in patients with renal disease. 
Meloxicam penetration into human red blood cells, after oral dosing, is less 
than 10%. Following a radiolabeled dose, over 90% of the radioactivity detected 
in the plasma was present as unchanged meloxicam. </paragraph>
                        <paragraph>Meloxicam concentrations in synovial fluid, after a single oral dose, range 
from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 
times higher than in plasma, due to the lower albumin content in synovial fluid 
as compared to plasma. The significance of this penetration is unknown. </paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Metabolism<paragraph>
                           <linkHtml href=""/>Meloxicam is extensively metabolized in the liver. 
Meloxicam metabolites include 5'-carboxy meloxicam (60% of dose), from P-450 
mediated metabolism formed by oxidation of an intermediate metabolite 
5'-hydroxymethyl meloxicam which is also excreted to a lesser extent (9% of 
dose). <content styleCode="italics">In vitro </content>studies indicate that CYP2C9 
(cytochrome P450 metabolizing enzyme) plays an important role in this metabolic 
pathway with a minor contribution of the CYP3A4 isozyme. Patientsâ€™ peroxidase 
activity is probably responsible for the other two metabolites which account for 
16% and 4% of the administered dose, respectively. All the four metabolites are 
not known to have any <content styleCode="italics">in vivo </content>pharmacological 
activity. </paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Excretion<paragraph>
                           <linkHtml href=""/>Meloxicam excretion is predominantly in the form of 
metabolites, and occurs to equal extents in the urine and feces. Only traces of 
the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). 
The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg 
doses: 0.5%, 6%, and 13% of the dose were found in urine in the form of 
meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively. 
There is significant biliary and/or enteral secretion of the drug. This was 
demonstrated when oral administration of cholestyramine following a single IV 
dose of meloxicam decreased the AUC of meloxicam by 50%. </paragraph>
                        <paragraph>The mean elimination half-life (t<sub>1/2</sub>) ranges from 15 
hours to 20 hours. The elimination half-life is constant across dose levels 
indicating linear metabolism within the therapeutic dose range. Plasma clearance 
ranges from 7 to 9 mL/min. </paragraph>
                        <linkHtml href=""/>
                        <linkHtml href=""/>
                        <linkHtml href=""/>Special Populations<paragraph>
                           <linkHtml href=""/>
                           <content styleCode="underline">Geriatric </content>
                        </paragraph>
                        <paragraph>Elderly males (â‰¥65 years of age) exhibited meloxicam plasma concentrations 
and steady-state pharmacokinetics similar to young males. Elderly females (â‰¥65 
years of age) had a 47% higher AUC<sub>ss</sub> and 32% higher 
C<sub>max</sub>,<sub>ss</sub> as compared to younger 
females (â‰¤55 years of age) after body weight normalization. Despite the 
increased total concentrations in the elderly females, the adverse event profile 
was comparable for both elderly patient populations. A smaller free fraction was 
found in elderly female patients in comparison to elderly male patients. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Gender </content>
                        </paragraph>
                        <paragraph>Young females exhibited slightly lower plasma concentrations relative to 
young males. After single doses of 7.5 mg meloxicam, the mean elimination 
half-life was 19.5 hours for the female group as compared to 23.4 hours for the 
male group. At steady state, the data were similar (17.9 hours vs 21.4 hours). 
This pharmacokinetic difference due to gender is likely to be of little clinical 
importance. There was linearity of pharmacokinetics and no appreciable 
difference in the C<sub>max</sub> or T<sub>max</sub> 
across genders. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hepatic Impairment </content>
                        </paragraph>
                        <paragraph>Following a single 15 mg dose of meloxicam there was no marked difference in 
plasma concentrations in patients with mild (Child-Pugh Class I) or moderate 
(Child-Pugh Class II) hepatic impairment compared to healthy volunteers. Protein 
binding of meloxicam was not affected by hepatic impairment. No dosage 
adjustment is necessary in patients with mild to moderate hepatic impairment. 
Patients with severe hepatic impairment (Child-Pugh Class III) have not been 
adequately studied. [<content styleCode="italics">see <linkHtml href="#ID48">Warnings and 
Precautions (5.3)</linkHtml> and <linkHtml href="#ID122">Use in Specific Populations 
(8.6)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Renal Impairment </content>
                        </paragraph>
                        <paragraph>Meloxicam pharmacokinetics have been investigated in subjects with mild and 
moderate renal impairment. Total drug plasma concentrations of meloxicam 
decreased and total clearance of meloxicam increased with the degree of renal 
impairment while free AUC values were similar in all groups. The higher 
meloxicam clearance in subjects with renal impairment may be due to increased 
fraction of unbound meloxicam which is available for hepatic metabolism and 
subsequent excretion. No dosage adjustment is necessary in patients with mild to 
moderate renal impairment. Patients with severe renal impairment have not been 
adequately studied. The use of meloxicam in subjects with severe renal 
impairment is not recommended [<content styleCode="italics">see <linkHtml href="#ID54">Warnings 
and Precautions (5.6)</linkHtml> and <linkHtml href="#ID124">Use in Specific Populations 
(8.7)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hemodialysis </content>
                        </paragraph>
                        <paragraph>Following a single dose of meloxicam, the free C<sub>max</sub> 
plasma concentrations were higher in patients with renal failure on chronic 
hemodialysis (1% free fraction) in comparison to healthy volunteers (0.3% free 
fraction). Hemodialysis did not lower the total drug concentration in plasma; 
therefore, additional doses are not necessary after hemodialysis. Meloxicam is 
not dialyzable. [<content styleCode="italics">see <linkHtml href="#ID22">Dosage and 
Administration (2.1)</linkHtml>, <linkHtml href="#ID54">Warnings and Precautions (5.6)</linkHtml> and 
<linkHtml href="#ID124">Use in Specific Populations (8.7)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Drug Interactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Aspirin: </content>When meloxicam is administered with 
aspirin (1000 mg three times daily) to healthy volunteers, it tended to increase 
the AUC (10%) and C<sub>max</sub> (24%) of meloxicam. The clinical 
significance of this interaction is not known [<content styleCode="italics">see <linkHtml href="#ID94">Drug Interactions (7.2)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cholestyramine: </content>Pretreatment for four days with 
cholestyramine significantly increased the clearance of meloxicam by 50%. This 
resulted in a decrease in t<sub>1/2</sub>, from 19.2 hours to 12.5 
hours, and a 35% reduction in AUC. This suggests the existence of a 
recirculation pathway for meloxicam in the gastrointestinal tract. The clinical 
relevance of this interaction has not been established. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cimetidine: </content>Concomitant administration of 200 mg 
cimetidine four times daily did not alter the single-dose pharmacokinetics of 30 
mg meloxicam. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Digoxin: </content>Meloxicam 15 mg once daily for 7 days did 
not alter the plasma concentration profile of digoxin after Î²-acetyldigoxin 
administration for 7 days at clinical doses. <content styleCode="italics">In vitro 
</content>testing found no protein binding drug interaction between digoxin and 
meloxicam. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Lithium: </content>In a study conducted in healthy subjects, 
mean pre-dose lithium concentration and AUC were increased by 21% in subjects 
receiving lithium doses ranging from 804 to 1072 mg twice daily with meloxicam 
15 mg QD every day as compared to subjects receiving lithium alone [<content styleCode="italics">see <linkHtml href="#ID98">Drug Interactions (7.4)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Methotrexate: </content>A study in 13 rheumatoid arthritis 
(RA) patients evaluated the effects of multiple doses of meloxicam on the 
pharmacokinetics of methotrexate taken once weekly. Meloxicam did not have a 
significant effect on the pharmacokinetics of single doses of methotrexate. 
<content styleCode="italics">In vitro</content>, methotrexate did not displace meloxicam 
from its human serum binding sites [<content styleCode="italics">see <linkHtml href="#ID100">Drug Interactions (7.5)</linkHtml>]. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Warfarin: </content>The effect of meloxicam on the 
anticoagulant effect of warfarin was studied in a group of healthy subjects 
receiving daily doses of warfarin that produced an INR (International Normalized 
Ratio) between 1.2 and 1.8. In these subjects, meloxicam did not alter warfarin 
pharmacokinetics and the average anticoagulant effect of warfarin as determined 
by prothrombin time. However, one subject showed an increase in INR from 1.5 to 
2.1. Caution should be used when administering meloxicam with warfarin since 
patients on warfarin may experience changes in INR and an increased risk of 
bleeding complications when a new medication is introduced [<content styleCode="italics">see <linkHtml href="#ID104">Drug Interactions (7.7)</linkHtml>]. </content>
                        </paragraph>
                     </text>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="7022694a-71ca-48bf-918e-d18b599a7892"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13. NONCLINICAL TOXICOLOGY</title>
               <text>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>13.1 Carcinogenesis, Mutagenesis, Impairment Of 
Fertility</content>
                  <paragraph>
                     <linkHtml href="#section-"/>
                     <content styleCode="italics">Carcinogenesis: </content>There was no 
increase in tumor incidence in long-term carcinogenicity studies in rats (104 
weeks) and mice (99 weeks) administered meloxicam at oral doses up to 0.8 
mg/kg/day in rats and up to 8.0 mg/kg/day in mice (up to 0.5- and 2.6-fold, 
respectively, the maximum recommended human daily dose based on body surface 
area comparison). </paragraph>
                  <paragraph>
                     <content styleCode="italics">Mutagenesis: </content>Meloxicam was not mutagenic in an 
Ames assay, or clastogenic in a chromosome aberration assay with human 
lymphocytes and an <content styleCode="italics">in vivo </content>micronucleus test in mouse 
bone marrow. </paragraph>
                  <paragraph>
                     <content styleCode="italics">Impairment of Fertility: </content>Meloxicam did not impair 
male and female fertility in rats at oral doses up to 9 mg/kg/day in males and 5 
mg/kg/day in females (up to 5.8- and 3.2-fold greater, respectively, than the 
maximum recommended human daily dose based on body surface area comparison). 
</paragraph>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="6969f006-2d0e-4854-aa9b-105943cbfb14"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14. CLINICAL STUDIES</title>
               <text>
                  <linkHtml href="#section-"/>
                  <content styleCode="bold">
                     <br/>14.1 Osteoarthritis and Rheumatoid Arthritis</content>
                  <paragraph>
                     <linkHtml href="#section-"/>The use of meloxicam for the treatment of the signs and 
symptoms of osteoarthritis of the knee and hip was evaluated in a 12-week, 
double-blind, controlled trial. Meloxicam (3.75 mg, 7.5 mg, and 15 mg daily) was 
compared to placebo. The four primary endpoints were investigatorâ€™s global 
assessment, patient global assessment, patient pain assessment, and total WOMAC 
score (a self-administered questionnaire addressing pain, function, and 
stiffness). Patients on meloxicam 7.5 mg daily and meloxicam 15 mg daily showed 
significant improvement in each of these endpoints compared with placebo. </paragraph>
                  <paragraph>The use of meloxicam for the management of signs and symptoms of 
osteoarthritis was evaluated in six double-blind, active-controlled trials 
outside the U.S. ranging from 4 weeksâ€™ to 6 monthsâ€™ duration. In these trials, 
the efficacy of meloxicam, in doses of 7.5 mg/day and 15 mg/day, was comparable 
to piroxicam 20 mg/day and diclofenac SR 100 mg/day and consistent with the 
efficacy seen in the U.S. trial. </paragraph>
                  <paragraph>The use of meloxicam for the treatment of the signs and symptoms of 
rheumatoid arthritis was evaluated in a 12-week, double-blind, controlled 
multinational trial. Meloxicam (7.5 mg, 15 mg, and 22.5 mg daily) was compared 
to placebo. The primary endpoint in this study was the ACR20 response rate, a 
composite measure of clinical, laboratory, and functional measures of RA 
response. Patients receiving meloxicam 7.5 mg and 15 mg daily showed significant 
improvement in the primary endpoint compared with placebo. No incremental 
benefit was observed with the 22.5 mg dose compared to the 15 mg dose.</paragraph>
               </text>
               <effectiveTime value="20110908"/>
            </section>
         </component>
         <component>
            <section>
               <id root="9a0f118e-a215-4a4f-a084-eafb3b638910"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16. HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <linkHtml href=""/>Meloxicam Tablets USP are available as light yellow, round, 
flat, uncoated tablets containing meloxicam 7.5 mg or as light yellow, oblong, 
biconvex, uncoated tablets containing meloxicam 15 mg. The 7.5 mg tablet is 
impressed with letter U and L on one side and tablet code 7.5 on the other side. 
The 15 mg tablet is impressed with letter U and L on one side and tablet code 15 
on the other side.</paragraph>
                  <paragraph>Meloxicam Tablets USP 7.5 mg are available as follows:</paragraph>
                  <paragraph>NDC 29300-124-13; Bottles of 30</paragraph>
                  <paragraph>NDC 29300-124-01; Bottles of 100</paragraph>
                  <paragraph>NDC 29300-124-10; Bottles of 1000</paragraph>
                  <paragraph>NDC 29300-124-50; Bottles of 5000</paragraph>
                  <paragraph>Meloxicam Tablets USP 15 mg are available as follows:</paragraph>
                  <paragraph>NDC 29300-125-13; Bottles of 30</paragraph>
                  <paragraph>NDC 29300-125-01; Bottles of 100</paragraph>
                  <paragraph>NDC 29300-125-10; Bottles of 1000</paragraph>
                  <paragraph>NDC 29300-125-50; Bottles of 5000</paragraph>
                  <paragraph>
                     <content styleCode="italics">Storage</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at Controlled Room Temperature 20<sup>0</sup>-25<sup>0</sup>C (68<sup>0</sup>-77<sup>0</sup>F) [See USP]. </content>Keep Meloxicam 
Tablets USP in a dry place</paragraph>
                  <paragraph>Dispense tablets in a tight container.</paragraph>
                  <paragraph>Keep this and all medications out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20110908"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM2">
                     <text>Logo Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="MeloxicamLogo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="63c02e6f-7464-4dd6-8654-32d5b448ec47"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>17. PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="italics">See FDA-approved Medication Guide 
</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Patients should be informed of the following information 
before initiating therapy with an NSAID and periodically during the course of 
ongoing therapy</content>.</paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold"/>
                  <br/>
                  <content styleCode="bold">17.1 Medication Guide</content>
                  <paragraph>
                     <linkHtml href=""/>Inform patients of the availability of a Medication Guide 
for NSAIDs that accompanies each prescription dispensed, and instruct them to 
read the Medication Guide prior to using meloxicam tablets. </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold"/>
                  <br/>
                  <content styleCode="bold">17.2 Cardiovascular Effects</content>
                  <paragraph>
                     <linkHtml href=""/>NSAIDS including meloxicam tablets, may cause serious CV 
side effects, such as MI or stroke, which may result in hospitalization and even 
death. Although serious CV events can occur without warning symptoms, patients 
should be alert for the signs and symptoms of chest pain, shortness of breath, 
weakness, slurring of speech, and should ask for medical advice when observing 
any indicative sign or symptoms. Patients should be apprised of the importance 
of this follow-up [<content styleCode="italics">see <linkHtml href="#ID44">Warnings and 
Precautions (5.1)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold"/>
                  <br/>
                  <content styleCode="bold">17.3 Gastrointestinal Effects</content>
                  <paragraph>
                     <linkHtml href=""/>NSAIDS including meloxicam tablets, can cause GI discomfort 
and, rarely, serious GI side effects, such as ulcers and bleeding, which may 
result in hospitalization and even death. Although serious GI tract ulcerations 
and bleeding can occur without warning symptoms, patients should be alert for 
the signs and symptoms of ulcerations and bleeding, and should ask for medical 
advice when observing any indicative sign or symptoms including epigastric pain, 
dyspepsia, melena, and hematemesis. Patients should be apprised of the 
importance of this follow-up [<content styleCode="italics">see <linkHtml href="#ID46">Warnings 
and Precautions (5.2)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold"/>
                  <br/>
                  <content styleCode="bold">17.4 Hepatotoxicity</content>
                  <paragraph>
                     <linkHtml href=""/>Inform patients of the warning signs and symptoms of 
hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper 
quadrant tenderness, and "flu-like" symptoms). If these occur, instruct patients 
to stop therapy and seek immediate medical therapy [<content styleCode="italics">see <linkHtml href="#ID48">Warnings and Precautions (5.3)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold"/>
                  <br/>
                  <content styleCode="bold">17.5 Adverse Skin Reactions</content>
                  <paragraph>
                     <linkHtml href=""/>NSAIDS, including meloxicam tablets, can cause serious skin 
side effects such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and 
toxic epidermal necrolysis (TEN), which may result in hospitalization and even 
death. Although serious skin reactions may occur without warning, patients 
should be alert for the signs and symptoms of skin rash and blisters, fever, or 
other signs of hypersensitivity such as itching, and should ask for medical 
advice when observing any indicative signs or symptoms. Advise patients to stop 
the drug immediately if they develop any type of rash and contact their 
physicians as soon as possible [<content styleCode="italics">see <linkHtml href="#ID58">Warnings 
and Precautions (5.8)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold"/>
                  <br/>
                  <content styleCode="bold">17.6 Weight Gain and Edema</content>
                  <paragraph>
                     <linkHtml href=""/>Advise patients to promptly report signs or symptoms of 
unexplained weight gain or edema to their physicians [<content styleCode="italics">see <linkHtml href="#ID52">Warnings and Precautions (5.5)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold"/>
                  <br/>
                  <content styleCode="bold">17.7 Anaphylactoid Reactions</content>
                  <paragraph>
                     <linkHtml href=""/>Inform patients of the signs of an anaphylactoid reaction 
(e.g., difficulty breathing, swelling of the face or throat). Instruct patients 
to seek immediate emergency help [<content styleCode="italics">see <linkHtml href="#ID56">Warnings and Precautions (5.7)</linkHtml>]. </content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <content styleCode="bold"/>
                  <br/>
                  <content styleCode="bold">17.8 Effects During Pregnancy</content>
                  <paragraph>
                     <linkHtml href=""/>Starting at 30 weeks gestation, meloxicam should be avoided 
as premature closure of the ductus arteriosus in the fetus may occur <content styleCode="italics">[see <linkHtml href="#ID60">Warnings and Precautions (5.9)</linkHtml> and <linkHtml href="#ID109">Use in Specific Populations (8.1)</linkHtml>].</content>
                  </paragraph>
                  <linkHtml href=""/>
                  <linkHtml href=""/>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Please address medical inquiries to 
1-866-562-4616</content>
                  </paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">UNICHEM LABORATORIES LTD.</content>
                  </paragraph>
                  <paragraph>Pilerne Ind. Estate,</paragraph>
                  <paragraph>Pilerne, Bardez, Goa 403511, India</paragraph>
                  <paragraph>Marketed by:</paragraph>
                  <br/>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>
                     <linkHtml href=""/>Rochelle Park, NJ 07662</paragraph>
                  <paragraph>13003755</paragraph>
                  <paragraph>R-03-03/2011</paragraph>
               </text>
               <effectiveTime value="20110913"/>
            </section>
         </component>
         <component>
            <section>
               <id root="4ee5c8b7-0e85-4e98-8dee-e34387fd89ef"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs.) </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">(See the end of this Medication Guide for a list of 
prescription NSAID medicines.)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I know about 
medicines called Non - Steroidal Anti-Inflammatory Drugs (NSAIDs)?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines may increase the chance of a heart attack or 
stroke that can lead to death. </content>This chance increases:</paragraph>
                  <list listType="unordered" ID="if4836dfc-ac53-4d1c-8371-d16090ae74f2">
                     <item>with longer use of NSAID medicines 
</item>
                     <item>in people who have heart disease </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">NSAID medicines should never be used right 
before or after a heart surgery called a "coronary artery bypass graft 
(CABG)."</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NSAID medicines can cause ulcers and bleeding in the stomach 
and intestines time during treatment. Ulcers bleeding:</content>
                  </paragraph>
                  <list listType="unordered" ID="id92400cd-4bcd-4cff-805a-583b0028598b">
                     <item>can happen without warning symptoms 
</item>
                     <item>may cause death </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">The chance of a person getting an ulcer or 
bleeding increases with:</content>
                  </paragraph>
                  <list listType="unordered" ID="i337e19a0-ed6d-4f38-89b8-03128828ca78">
                     <item>taking medicines called "corticosteroids" and "anticoagulants" 
</item>
                     <item>longer use 
</item>
                     <item>smoking 
</item>
                     <item>drinking alcohol 
</item>
                     <item>older age 
</item>
                     <item>having poor health </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">NSAID medicines should only be 
used:</content>
                  </paragraph>
                  <list listType="unordered" ID="i24c13bbb-fd2b-44c3-87b6-a619e7099100">
                     <item>exactly as prescribed 
</item>
                     <item>at the lowest dose possible for your treatment 
</item>
                     <item>for the shortest time needed </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">What are Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDs)?</content>
                  </paragraph>
                  <paragraph>NSAID medicines are used to treat pain and redness, swelling, and heat 
(inflammation) from medical conditions such as:</paragraph>
                  <list listType="unordered" ID="if323f63b-0cdf-46a1-8ffd-123907fe4219">
                     <item>different types of arthritis 
</item>
                     <item>menstrual cramps and other types of short-term pain </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Who should not take a Non-Steroidal 
Anti-Inflammatory Drug (NSAID)?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not take an NSAID medicine:</content>
                  </paragraph>
                  <list listType="unordered" ID="iff919c07-d1a4-4c6c-8aef-b462d5983d14">
                     <item>if you had an asthma attack, hives, or other allergic reaction with aspirin 
or any other NSAID medicine 
</item>
                     <item>for pain right before or after heart bypass surgery </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Tell your healthcare provider:</content>
                  </paragraph>
                  <list listType="unordered" ID="i35e848f8-0983-4b3f-8a38-84f036d88148">
                     <item>about all of your medical conditions 
</item>
                     <item>about all of the medicines you take. NSAIDs and some other medicines can 
interact with each other and cause serious side effects. <content styleCode="bold">Keep a 
list of your medicines to show to your healthcare provider and pharmacist. 
</content>
                     </item>
                     <item>if you are pregnant. NSAID medicines should not be used by pregnant and 
women late in their pregnancy. 
</item>
                     <item>if you are breastfeeding. Talk to your doctor. </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">What are the possible side effects of 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Serious side effects include:</content>
                  </paragraph>
                  <list listType="unordered" ID="i7b8137e8-94c5-4c51-85ee-445bacb94efc">
                     <item>heart attack 
</item>
                     <item>stroke 
</item>
                     <item>high blood pressure 
</item>
                     <item>heart failure from body swelling (fluid retention) 
</item>
                     <item>kidney problems including kidney failure 
</item>
                     <item>bleeding and ulcers in the stomach and intestine 
</item>
                     <item>low red blood cells (anemia) 
</item>
                     <item>life-threatening skin reactions 
</item>
                     <item>life-threatening allergic reactions 
</item>
                     <item>liver problems including liver failure 
</item>
                     <item>asthma attacks in people who have asthma </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Other side effects include:</content>
                  </paragraph>
                  <list listType="unordered" ID="i9cfd6b59-6d64-4ae5-86f5-0b7f1959997c">
                     <item>stomach pain 
</item>
                     <item>constipation 
</item>
                     <item>diarrhea 
</item>
                     <item>gas 
</item>
                     <item>heartburn 
</item>
                     <item>nausea 
</item>
                     <item>vomiting 
</item>
                     <item>dizziness </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Get emergency help right away if you have 
any of the following symptoms:</content>
                  </paragraph>
                  <list listType="unordered" ID="ia190a1fb-2e67-4cab-8e72-284f75344ae1">
                     <item>shortness of breath or trouble breathing 
</item>
                     <item>chest pain 
</item>
                     <item>weakness in one part or side of your body 
</item>
                     <item>slurred speech 
</item>
                     <item>swelling of the face or throat </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="bold">Stop your NSAID medicine and call your 
healthcare provider right away if you have any of the following symptoms: 
</content>
                  </paragraph>
                  <list listType="unordered" ID="i37449d4b-8c40-4c0e-8b6d-4ec79a0d562e">
                     <item>nausea 
</item>
                     <item>more tired or weaker than usual 
</item>
                     <item>itching 
</item>
                     <item>your skin or eyes look yellow 
</item>
                     <item>stomach pain 
</item>
                     <item>flu-like symptoms 
</item>
                     <item>vomit blood 
</item>
                     <item>there is blood in your bowel movement or it is black and sticky like tar 
</item>
                     <item>unusual weight gain 
</item>
                     <item>skin rash or blisters with fever 
</item>
                     <item>swelling of the arms and legs, hands and feet </item>
                  </list>
                  <paragraph>
                     <linkHtml href=""/>These are not all the side effects with NSAID medicines. 
Talk to your healthcare provider or pharmacist for more information about NSAID 
medicines.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Call your doctor for medical advice about side effects. You 
may report side effects to FDA at 1800-FDA-1088. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Other information about Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDs)</content>
                  </paragraph>
                  <list listType="unordered" ID="i20eeba23-7664-4440-88f9-14e5d67e989e">
                     <item>Aspirin is an NSAID medicine but it does not increase the chance of a heart 
attack. Aspirin can cause bleeding in the brain, stomach, and intestines. 
Aspirin can also cause ulcers in the stomach and intestines. 
</item>
                     <item>Some of these NSAID medicines are sold in lower doses without a prescription 
(over-the-counter). Talk to your healthcare provider before using 
over-the-counter NSAIDs for more than 10 days.</item>
                  </list>
                  <content>NSAID medicines that need prescription<br/>
                     <br/>
                     <br/>
                  </content>
                  <table width="100%" ID="i1fdc839b-1fc9-4a93-8836-4aa4759ae8da">
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">GenericÂ </content>
                              <content styleCode="bold">Name</content>
                              <br/>
                           </td>
                           <td>
                              <content styleCode="bold">Tradename</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Celecoxib<br/>
                           </td>
                           <td>Celebrex<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Diclofenac<br/>
                           </td>
                           <td>Cataflam,Â Voltaren,Â ArthrotecÂ (combinedÂ withÂ misoprostol)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Diflunisal<br/>
                           </td>
                           <td>Dolobid<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Etodolac<br/>
                           </td>
                           <td>Lodine,Â LodineÂ XL<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Fenoprofen<br/>
                           </td>
                           <td>Nalfon,Â NalfonÂ 200<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Flurbiprofen<br/>
                           </td>
                           <td>Ansaid<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Ibuprofen<br/>
                           </td>
                           <td>Motrin,Â Tab-Profen,Â Vicoprofen*Â (combinedÂ withÂ hydrocodone),Â CombunoxÂ (combinedÂ withÂ oxycodone)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Indomethacin<br/>
                           </td>
                           <td>Indocin,Â IndocinÂ SR,Â Indo-Lemmon,Â Indomethagan<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Ketoprofen<br/>
                           </td>
                           <td>Oruvail<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Ketorolac<br/>
                           </td>
                           <td>Toradol<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>MefenamicÂ Acid<br/>
                           </td>
                           <td>Ponstel<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Meloxicam<br/>
                           </td>
                           <td>Mobic<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Nabumetone<br/>
                           </td>
                           <td>Relafen<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Naproxen<br/>
                           </td>
                           <td>Naprosyn,Â Anaprox,Â AnaproxÂ DS,Â EC-Â Naprosyn,Â Naprelan,Â NaprapacÂ (co-packagedÂ withÂ lansoprazole)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Oxaprozin<br/>
                           </td>
                           <td>Daypro<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Piroxicam<br/>
                           </td>
                           <td>Feldene<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Sulindac<br/>
                           </td>
                           <td>Clinoril<br/>
                           </td>
                        </tr>
                        <tr>
                           <td>Tolmetin<br/>
                           </td>
                           <td>Tolectin,Â TolectinÂ DS,Â TolectinÂ 600<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
                  <paragraph>
                     <linkHtml href=""/>
                     <content styleCode="italics">This Medication Guide has been approved 
by the U.S. Food and Drug Administration.</content>
                  </paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">UNICHEM LABORATORIES LTD.</content>
                  </paragraph>
                  <paragraph>Pilerne Ind. Estate,</paragraph>
                  <paragraph>Pilerne, Bardez, Goa 403511, India</paragraph>
                  <paragraph>Marketed by:</paragraph>
                  <br/>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>
                     <linkHtml href=""/>Rochelle Park, NJ 07662</paragraph>
                  <paragraph>13002550</paragraph>
                  <paragraph>R-02-09/2010</paragraph>
               </text>
               <effectiveTime value="20110913"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e58c49d5-0d9b-4e9b-b099-b2e71bf476c0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - MELOXICAM   7.5 MG  TABLET</title>
               <text>
                  <br/>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM3"/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20110914"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM3">
                     <text>Label Image </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="MELOXICAM 7.5MG LABEL.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="ef7f1af9-e3da-4c82-9c6e-5face618ea4c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - MELOXICAM  15 MG  TABLET</title>
               <text>
                  <br/>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM4"/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20110914"/>
               <component>
                  <observationMedia classCode="OBS" moodCode="EVN" ID="MM4">
                     <text>Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="MELOXICAM 15MG LABEL.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>